Why One Fund Made a $23 Million Bet on This Addiction-Treatment Stock Amid a Staggering Rally

Claret Asset Management disclosed a new 707,267-share stake in Indivior valued at $23.36 million at average quarter pricing, with a quarter-end value of $21.56 million, equal to 2.58% of its reportable AUM. The filing comes alongside strong operating momentum at Indivior, including Q1 revenue up 19% to $317 million, Sublocade sales up 32% to $232 million, and record adjusted EBITDA of $164 million. The company also raised guidance and continued aggressive capital returns, including roughly $125 million of buybacks and a new $175 million accelerated repurchase agreement.

Analysis

This is less a “new idea” signal than a confirmation that the market’s highest-conviction healthcare capital is rotating into a name with improving operating leverage. When a meaningful allocator initiates a mid-cap specialty pharma position after a 12-month run, it usually reflects confidence that earnings revisions are still ahead of price and that the commercial curve is underappreciated. The key second-order effect is that stronger buyback execution plus refinancing lowers equity duration: each incremental dollar of free cash flow now has a higher probability of returning directly to shareholders rather than being absorbed by balance sheet repair.

The real debate is not whether the franchise is improving, but whether the current multiple already discounts the next 12-18 months of prescription growth. If the core product continues taking share, the market may start valuing INDV less like a post-turnaround recovery name and more like a cash-generative branded pharma platform, which would justify multiple expansion even if growth decelerates from the latest quarter. That said, the stock is now vulnerable to any sign of normalization in script momentum, payer pushback, or a slowdown in capital return cadence, because the re-rating has likely pulled forward a large chunk of good news.

The contrarian miss is that the bull case may be less about peak growth and more about the durability of conversion from revenue into buybacks. If management can keep pairing deleveraging with repurchases, the equity can compound even if top-line growth moderates, because per-share earnings should rise faster than operating income. But the setup is crowded enough that a single guidance hiccup could compress multiple quickly; after this kind of run, a 10-15% drawdown on any quarter with softer net adds would not be surprising.

Key Decisions for Investors

• Long INDV on a 3-6 month horizon into the next earnings print; thesis is that continued Sublocade momentum plus buybacks can drive another leg of EPS revisions. Risk/reward is attractive if the stock can re-rate from a growth-recovery multiple to a cash-generative specialty pharma multiple, but size modestly given the extended move.
• Use a call spread in INDV rather than outright equity for defined risk: buy 3-6 month calls and sell a higher strike against them to monetize implied volatility after the run. This captures upside from a guidance raise or strong prescription data while limiting multiple compression risk.
• Pair trade: long INDV / short a basket of slower-growth specialty pharma names with weaker capital return profiles over 1-2 quarters. The idea is to isolate the market’s willingness to pay for visible cash conversion and shareholder yield rather than pure sector beta.
• If already long, tighten risk management ahead of earnings and prescription-trend data; trim 25-33% into strength if the stock gaps higher on good numbers, because post-peak-growth de-rating risk increases once the market starts demanding proof of sustainability.
• Watch for an entry reset on any 10-15% pullback caused by a temporary sentiment shakeout rather than fundamental deterioration; that would likely offer the best risk/reward versus chasing after a 260% one-year move.